|
| 36166727 | Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134. | J Clin Oncol | 2023 |
| 37857711 | The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial. | Nat Med | 2023 |
| 37592104 | Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial. | Nat Med | 2023 |
| 37835565 | Randomized Phase 2 Clinical Trial of Olaratumab in Combination with Gemcitabine and Docetaxel in Advanced Soft Tissue Sarcomas. | Cancers (Basel) | 2023 |
| 37870955 | Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma. | N Engl J Med | 2023 |
| 37292676 | The landscape of drug sensitivity and resistance in sarcoma. | bioRxiv | 2023 |
| 37000164 | Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial. | Clin Cancer Res | 2023 |
| 36890230 | Neoantigen-targeted CD8<sup>+</sup> T cell responses with PD-1 blockade therapy. | Nature | 2023 |
| 36856617 | Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. | N Engl J Med | 2023 |
| 36581724 | Lifelong Imaging Surveillance is Indicated for Patients with Primary Retroperitoneal Liposarcoma. | Ann Surg Oncol | 2023 |
| 36690841 | ASO Visual Abstract: Lifelong Imaging Surveillance is Indicated for Patients with Primary Retroperitoneal Liposarcoma. | Ann Surg Oncol | 2023 |
| 36136304 | Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy. | Clin Cancer Res | 2023 |
| 36356599 | Non-viral precision T cell receptor replacement for personalized cell therapy. | Nature | 2023 |
| 34716196 | Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT. | Clin Cancer Res | 2022 |
| 35394800 | Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial. | J Clin Oncol | 2022 |
| 36215947 | A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2Â and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery. | Eur J Cancer | 2022 |
| 35040698 | CSF1 receptor inhibition of tenosynovial giant cell tumor using novel disease-specific MRI measures of tumor burden. | Future Oncol | 2022 |
| 35307963 | Retrospective analysis of adjuvant treatment for localized, operable uterine leiomyosarcoma. | Cancer Med | 2022 |
| 34764195 | Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma. | Cancer Discov | 2022 |
| 34407970 | A Randomized Phase II Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab in Patients with Advanced Gastrointestinal Stromal Tumors. | Clin Cancer Res | 2022 |
| 33306984 | Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. | Cancer Cell | 2021 |
| 33845460 | NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021. | J Natl Compr Canc Netw | 2021 |
| 33855868 | Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma. | Future Oncol | 2021 |
| 34898540 | Management of Clitoral Melanoma Presenting as an Exophytic Clitoral Mass: A Case Report and Review of the Literature. | Curr Oncol | 2021 |
| 34326162 | Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma. | Cancer Discov | 2021 |
| 33400014 | Translating Knowledge About the Immune Microenvironment of Gastrointestinal Stromal Tumors into Effective Clinical Strategies. | Curr Treat Options Oncol | 2021 |
| 32472503 | Patient Experiences with Avelumab in Treatment-Naïve Metastatic Merkel Cell Carcinoma: Longitudinal Qualitative Interview Findings from JAVELIN Merkel 200, a Registrational Clinical Trial. | Patient | 2020 |
| 32054730 | A Phase II Trial of 5-Day Neoadjuvant Radiotherapy for Patients with High-Risk Primary Soft Tissue Sarcoma. | Clin Cancer Res | 2020 |
| 33064988 | A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. | Cell | 2020 |
| 32846908 | Chemotherapy and Survival in Patients with Primary High-Grade Extremity and Trunk Soft Tissue Sarcoma. | Cancers (Basel) | 2020 |
| 32755981 | Low Rates of Chemotherapy Use for Primary, High-Grade Soft Tissue Sarcoma: A National Cancer Database Analysis. | J Natl Compr Canc Netw | 2020 |
| 30573690 | A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab. | Clin Cancer Res | 2019 |
| 30024282 | Patterns of sensitivity to a panel of drugs are highly individualised for undifferentiated/unclassified soft tissue sarcoma (USTS) in patient-derived orthotopic xenograft (PDOX) nude-mouse models. | J Drug Target | 2019 |
| 30894212 | Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma. | J Immunother Cancer | 2019 |
| 30945965 | Health Care Resource Utilization and Costs in First-Line Treatments for Patients with Metastatic Melanoma in the United States. | J Manag Care Spec Pharm | 2019 |
| 31034598 | A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft-tissue sarcomas. | Cancer | 2019 |
| 30576761 | Tumor mutational burden and response to programmed cell death protein 1 inhibitors in a case series of patients with metastatic desmoplastic melanoma. | J Am Acad Dermatol | 2019 |
| 28640064 | Predictors of Local Recurrence in Patients With Myxofibrosarcoma. | Am J Clin Oncol | 2018 |
| 30166061 | Combination therapy of tumor-targeting Salmonella typhimurium A1-R and oral recombinant methioninase regresses a BRAF-V600E-negative melanoma. | Biochem Biophys Res Commun | 2018 |
| 30075584 | Direct costs associated with adverse events of systemic therapies for advanced melanoma: Systematic literature review. | Medicine (Baltimore) | 2018 |
| 30292411 | A combination of irinotecan/cisplatinum and irinotecan/temozolomide or tumor-targeting Salmonella typhimurium A1-R arrest doxorubicin- and temozolomide-resistant myxofibrosarcoma in a PDOX mouse model. | Biochem Biophys Res Commun | 2018 |
| 30392912 | Metabolic targeting with recombinant methioninase combined with palbociclib regresses a doxorubicin-resistant dedifferentiated liposarcoma. | Biochem Biophys Res Commun | 2018 |
| 29528792 | Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT). | J Clin Oncol | 2018 |
| 29389232 | How Should We Assess Benefit in Patients Receiving Checkpoint Inhibitor Therapy? | J Clin Oncol | 2018 |
| 29470191 | Characterization of Postinfusion Phenotypic Differences in Fresh Versus Cryopreserved TCR Engineered Adoptive Cell Therapy Products. | J Immunother | 2018 |
| 29384032 | Individualized doxorubicin sensitivity testing of undifferentiated soft tissue sarcoma (USTS) in a patient-derived orthotopic xenograft (PDOX) model demonstrates large differences between patients. | Cell Cycle | 2018 |
| 29664796 | Long-term Outcomes With Ifosfamide-based Hypofractionated Preoperative Chemoradiotherapy for Extremity Soft Tissue Sarcomas. | Am J Clin Oncol | 2018 |
| 29566106 | Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial. | JAMA Oncol | 2018 |
| 29336888 | LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer. | Cell | 2018 |
| 28941311 | Endocrinopathies with use of cancer immunotherapies. | Clin Endocrinol (Oxf) | 2018 |